To date, a few randomized controlled trials (RCTs) have focused on the efficacy and safety of PD-1 inhibitors as second-line agents beyond chemotherapy for the treatment of advanced ESCC. Here, PDCD1 is linked to esophageal squamous cell carcinoma.